Search Result

Results for "

TNKS

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AAK1 (1) Apoptosis (3) Aurora Kinase (1) Bcr-Abl (1) CaMK (1) CDK (2) Cyclin G-associated Kinase (GAK) (1) Epigenetic Reader Domain (1) ERK (1) Ferroptosis (2) LIM Kinase (LIMK) (2) LRRK2 (2) MAP4K (1) MAPKAPK2 (MK2) (1) PARP (30) PROTACs (3) Reverse Transcriptase (1) Salt-inducible Kinase (SIK) (2) Small Interfering RNA (siRNA) (9) Tyrosinase (3) ULK (2) Wnt (1) β-catenin (2)
By Research Areas:	Cancer (37) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (2) Metabolic Disease (2) Neurological Disease (2)
Oligonucleotides:	Pre-designed siRNA Sets (9) siRNAs (9)

Inhibitors & Agonists

Recombinant Proteins

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-23338

TNKS-2-IN-1	PARP	Others
TNKS-2-IN-1 (Compound 13g) is a *TNKS-2* inhibitor. TNKS-2-IN-1 inhibits TNKS-1 and TNKS-2 with IC₅₀s of 259 nM and 1100 nM .

HY-13990

*NVP-TNKS656* TNKS656	PARP Apoptosis	Cancer
NVP-TNKS656 is a highly potent, selective, and orally active *TNKS2* inhibitor with IC₅₀ of 6 nM, and is > 300 fold selectivity against PARP1 and PARP2.

HY-156332

TNKS-2-IN-2	PARP	Cancer
TNKS-2-IN-2 is a potent and selective inhibitor of *TNKS2* with an IC₅₀ of 22 nM .

HY-12601

TNKS 22 TNKS-IN-22	PARP	Cancer
TNKS 22 (compound 22) is an orally active and selective tankyrase inhibitor. TNKS 22 inhibits *TNKS1* and *TNKS2* with IC₅₀s of 0.1 and 4.1 nM, respectively .

HY-153259

TNKS1/2-IN-2	PARP	Cancer
TNKS1/2-IN-2 (Compound 21) is a potent and selective tankyrases inhibitor. TNKS1/2-IN-2 exhibits IC₅₀ values of 4 nM and 63 nM against TNK1 and TNK2 in the enzymatic assay, respectively. TNKS1/2-IN-2 inhibits proliferation of A549 and H292 cell lines with IC₅₀ values of 39.5 nM and 12.8 nM, respectively. TNKS1/2-IN-2 can be used for the research of cancer .

HY-12577

TNKS1/2-IN-1	Others	Cancer
TNKS1/2-IN-1 is a potent tankyrase TNKS1/2 inhibitor with pIC₅₀s ranging from 7.1-8.2. TNKS1/2-IN-1 can be used for research of cancer, fibrosis, and other hyperproliferative diseases .

HY-117700

TNKS-IN-2	PARP	Cancer
TNKS-IN-2 (compound 40) is a potent and selective tankyrase (TNKS) inhibitor with pIC₅₀ values of 8.1, 7.0 for TANKS and Wnt, respectively .

HY-RS14839

TNKS Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TNKS Human Pre-designed siRNA Set A contains three designed siRNAs for TNKS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TNKS Human Pre-designed siRNA Set A TNKS Human Pre-designed siRNA Set A

HY-RS14840

Tnks Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tnks Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tnks gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tnks Mouse Pre-designed siRNA Set A Tnks Mouse Pre-designed siRNA Set A

HY-RS14841

Tnks Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tnks Rat Pre-designed siRNA Set A contains three designed siRNAs for Tnks gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tnks Rat Pre-designed siRNA Set A Tnks Rat Pre-designed siRNA Set A

HY-RS14843

TNKS2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TNKS2 Human Pre-designed siRNA Set A contains three designed siRNAs for TNKS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TNKS2 Human Pre-designed siRNA Set A TNKS2 Human Pre-designed siRNA Set A

HY-RS14844

Tnks2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tnks2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tnks2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tnks2 Mouse Pre-designed siRNA Set A Tnks2 Mouse Pre-designed siRNA Set A

HY-RS14845

TNKS2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TNKS2 Rat Pre-designed siRNA Set A contains three designed siRNAs for TNKS2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

TNKS2 Rat Pre-designed siRNA Set A TNKS2 Rat Pre-designed siRNA Set A

HY-RS14842

TNKS1BP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TNKS1BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TNKS1BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TNKS1BP1 Human Pre-designed siRNA Set A TNKS1BP1 Human Pre-designed siRNA Set A

HY-146336

*PARP1/2/TNKS1/2-IN-1*	PARP Apoptosis	Cancer
PARP1/2/TNKS1/2-IN-1 (Compound I-9) is a dual PARP-1, PARP-2, *TNKS1* and *TNKS2* inhibitor with IC₅₀ values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM against PARP-1, PARP-2, TNKS1 and TNKS2, respectively. PARP1/2/TNKS1/2-IN-1 exhibits favorable synergistic antitumor efficacy and induces apoptosis .

HY-123851

MSC2504877 M2912	PARP	Cancer
MSC2504877 (M2912) is a potent and orally active tankyrase inhibitor with IC₅₀s of 0.0007, 0.0008, 0.54 µM for TNKS, TNKS2, PARP1, respectively. MSC2504877 increases the expression of AXIN2 and TNKS protein levels and decreases β-catenin levels. MSC2504877 shows anti-tumor activity .

HY-145111

TNK2-IN-1	Tyrosinase	Cancer
TNK2-IN-1 is a *TNK2* inhibitor. TNK2-IN-1 has an IC₅₀ of 224 nM for TNK2. TNK2-IN-1 can be used for the research of cancer .

HY-118731

TNK-6123	Reverse Transcriptase	Infection
TNK-6123 is a potent Emivirine (HY-15353) analogue with improved activity against drug-resistant HIV mutants. TNK-6123 improves activity against Lys103Asn mutant RT .

HY-U00422

K-756 2 Publications Verification	PARP	Cancer
K-756 is a direct and selective tankyrase (TNKS) inhibitor, which inhibits the ADP-ribosylation activity of *TNKS1* and *TNKS2* with IC₅₀s of 31 and 36 nM, respectively.

HY-12418

Stenoparib 1 Publications Verification E7449; 2X-121	PARP	Cancer
Stenoparib (E7449) is a potent PARP1 and PARP2 inhibitor and also inhibits *TNKS1* and *TNKS2, with IC₅₀s of 2.0, 1.0, ∼50 and ∼50 nM for PARP1, PARP2, TNKS1 and TNKS*2, respectively, using ³²P-NAD ⁺ as substrate.

HY-13968

JW 55 2 Publications Verification	PARP	Cancer
JW 55 is a potent and selective β-catenin signaling pathway inhibitor, which functions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2). JW 55 decreases auto-PARsylation of TNKS1/2 in vitro with IC₅₀s of 1.9 μM and 830 nM respectively.

HY-121719

TIQ-A	PARP	Cardiovascular Disease Cancer
TIQ-A is a potent *TNKS* (poly-ART, PARP) inhibitor, with an IC₅₀ of 24 nM for *TNKS2*. TIQ-A is a potential anti-ischemic agent .

HY-12438

G007-LK 5+ Cited Publications	PARP	Cancer
G007-LK is a potent and selective inhibitor of *TNKS1* and *TNKS2, with IC₅₀*s of 46 nM and 25 nM, respectively.

HY-RS14837

TNK1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TNK1 Human Pre-designed siRNA Set A contains three designed siRNAs for TNK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TNK1 Human Pre-designed siRNA Set A TNK1 Human Pre-designed siRNA Set A

HY-RS14838

TNK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TNK2 Human Pre-designed siRNA Set A contains three designed siRNAs for TNK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TNK2 Human Pre-designed siRNA Set A TNK2 Human Pre-designed siRNA Set A

HY-19351

MN-64 3 Publications Verification	PARP	Cancer
MN-64 is a potent tankyrase 1 inhibitor, with IC₅₀s of 6 nM, 72 nM, 19.1 μM, and 39.4 μM for *TNKS1, TNKS*2, ARTD1 and ARTD2, respectively.

HY-153332

Tankyrase-IN-5	PARP	Cancer
Tankyrase-IN-5 (Compound 30f), an analogue of MSC2504877 (HY-123851), is a tankyrase *TNKS1* and *TNKS2* inhibitor with IC₅₀s of 2.3 nM and 7.9 nM, respectively .

HY-108845

Tenecteplase TNK-tPA	Others	Metabolic Disease
Tenecteplase (TNK-tPA) is a modified tissue plasminogen activator. Tenecteplase is a recombinant human tissue plasminogen activator (rt-PA) that has been bioengineered to produce mutations in three gene loci. Tenecteplase (TNK-tPA) can be used in the study of acute ischemic stroke .

HY-147886

PARP1-IN-11	PARP	Cancer
PARP1-IN-11 (compound 49) is a potent PARP1 inhibitor with IC₅₀ value of 0.082 µM. PARP1-IN-11 shows complete inhibition of PARP2 and substantially inhibits PARP3, TNKS1 and TNKS2 .

HY-126248

Tankyrase-IN-2	PARP	Cancer
Tankyrase-IN-2 (compound 5k) is a potent, selective, and orally active tankyrase inhibitor (IC₅₀s of 10, 7, and 710 nM for TNKS1, TNKS2 as well as PARP1, respectively). Tankyrase-IN-2 has favorable physicochemical profile and pharmacokinetic properties modulating Wnt pathway activity in a colorectal xenograft model .

HY-108516

TC-E 5001	PARP	Cancer
TC-E 5001 is an inhibitor of Wnt pathway that inhibits tankyrase 1/2 (TNKS1/2) via novel adenosine pocket binding, with K_ds of 79 nM and 28 nM, respectively. TC-E 5001 also inhibits Axin2 and STF, with IC₅₀s of 0.709 μM and 0.215 μM, respectively .

HY-12975

AZ6102 1 Publications Verification	PARP	Cancer
AZ6102 is a potent dual *TNKS1* and *TNKS2* inhibitor, with IC₅₀s of 3 nM and 1 nM, respectively, and alao has 100-fold selectivity against other PARP family enzymes, with IC₅₀s of 2.0 μM, 0.5 μM, and >3 μM, for PARP1, PARP2, and PARP6, respectively.

HY-15147

XAV-939 Maximum Cited Publications 129 Publications Verification	β-catenin PARP	Cancer
XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC₅₀ values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation .

HY-16910

WIKI4 2 Publications Verification	PARP β-catenin	Cancer
WIKI4 is a potent tankyrase inhibitor with an IC₅₀ of 26 nM for *TNKS2. WIKI4 potently inhibits Wnt/β-catenin* signaling and that its half-maximal response dose is 75 nM. WIKI4 mediates its effects on Wnt/β-catenin signaling by inhibiting the enzymatic activity of *TNKS2* . WIKI4 is cytotoxic to SCLC cells with an IC₅₀ value of 0.02 μM .

HY-147245

Basroparib STP1002	PARP	Cancer
Basroparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor with an IC₅₀ of 5.8 nM for *TNKS1*, exhibiting antitumor activity .

HY-152197

Tankyrase-IN-3	PARP	Cancer
Tankyrase-IN-3 is a tankyrase 1 (TNKS1) inhibitor with an IC₅₀ value of 22 nM. Tankyrase-IN-3 can be used for the research of cancer .

HY-145267

OM-153	PARP Wnt	Cancer
OM-153 is a potent and orally active tankyrase inhibitor with IC₅₀s of 13 nM and 2 nM for tankyrase 1 and tankyrase 2 (TNKS1/2), respectively. OM-153 inhibits luciferase-based Wnt/β-catenin signaling reporter activity with an IC₅₀ value of 0.63 nM. OM-153 shows inhibition of Wnt/β-catenin signaling and proliferation in COLO 320DM .

HY-15811

XMD8-87 ACK1-B19	Tyrosinase	Cancer
XMD8-87 is a potent *TNK2* inhibitor with IC₅₀ values of 38 and 113 nM for the D163E and R806Q mutations, respectively.

HY-101243

XMD16-5	Tyrosinase	Cancer
XMD16-5 is a potent *TNK2* inhibitor with IC₅₀ values of 16 and 77 nM for the D163E and R806Q mutations, respectively.

HY-152198

Tankyrase-IN-4	PARP	Cancer
Tankyrase-IN-4 is a tankyrase 1 (TNKS1) inhibitor with an IC₅₀ value of 0.8 nM. Tankyrase-IN-4 can be used for the research of cancer .

HY-147316

TP-5801	Others	Cancer
TP-5801 is an orally active *TNK1* (non-receptor tyrosine kinase) inhibitor (IC₅₀=1.40 nM), and shows anti-tumor activity .

HY-147316A

TP-5801 TFA	Others	Cancer
TP-5801 TFA is an orally active *TNK1* (non-receptor tyrosine kinase) inhibitor (IC₅₀=1.40 nM), and shows anti-tumor activity .

HY-137849

RK-582	PARP	Cancer
RK-582 is an orally active, spiroindoline-based selective inhibitor of tankyrase. The IC₅₀s of RK-582 against TNKS1/PARP5A and PARP1 are 36.1 nM and 18.168 nM, respectively. RK-582 inhibits rectal cancer COLO-320DM cells (GI50=0.23 μM) and significantly inhibits tumor growth in a COLO-320DM mouse xenograft model .

HY-100847

AZ0108	PARP	Cancer
AZ0108 is an inhibitor for poly ADP-ribose polymerase (PARP), which inhibits PARP1, PARP2, PARP3, PARP6, TNKS1, TNKS2, with IC₅₀s of <0.03, <0.03, 2.8, 0.083, 3.2, >3 μM, respectively. AZ0108 prevents centrosome clustering with an EC₅₀ of 0.053 μM, and exhibits cytotoxicity in cell OCI-LY-19 with GI₅₀ of 0.017 μM. AZ0108 exhibits good in vivo pharmacokinetic characters in rat/mouse models .

HY-143338

ART-IN-1	PARP	Cancer
ART-IN-1 (compound 7) is a selective PARP inhibitor with IC₅₀s of 19, 22, 2.4, >100, 1.1 µM for PARP2, TNKS2, PARP10, PARP14, PARP15, respectively .

HY-W294889

OUL245	PARP	Cancer
OUL245 is a 7-Hydroxy derivative, and a selectively PARP2 inhibitor (IC₅₀=44 nM). OUL245 also inhibits other PARP and TNKS enzymes with IC₅₀s of 2.9-8.8 μM .

HY-14443

XMD8-92 10+ Cited Publications	ERK Epigenetic Reader Domain	Cancer
XMD8-92 is a potent ERK5 (BMK1)/BRD4 inhibitor with K_ds of 80 and 190 nM, respectively. XMD8-92 inhibits DCAMKL2, PLK4 and TNK1 with K_ds of 190, 600 and 890 nM, respectively. Anti-cancer activity .

HY-155246

PARP1-IN-15	Apoptosis PARP	Cancer
PARP1-IN-15 (Compound 6) is a PARP1 inhibitor. PARP1-IN-15 inhibits tankyrase (TNKS) and facilitates DNA double-strand breaks damage. PARP1-IN-15 induces tumor cell apoptosis. PARP1-IN-15 has anti-cancer activity in triple-negative breast cancer (TNBC) cells and TNBC patient-derived organoids. PARP1-IN-15 can be used for research of TNBC with or without BRCA1 mutations .

HY-15800A

CZC-25146	LRRK2	Neurological Disease Inflammation/Immunology
CZC-25146 is a potent and orally active LRRK2 inhibitor with IC₅₀ values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 can be used to research Parkinson's disease and liver diseases .

HY-15800

CZC-25146 hydrochloride	LRRK2	Neurological Disease Inflammation/Immunology
CZC-25146 hydrochloride is a potent LRRK2 inhibitor with IC₅₀ values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 hydrochloride inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 hydrochloride prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 hydrochloride exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 hydrochloride can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 hydrochloride can be used to research Parkinson's disease and liver diseases .

Species:	Human (2)
Tag:	His (1) Tag Free (1)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P701631

	TNKS1 Protein, Human (His) TNKS; Poly [ADP-ribose] polymerase tankyrase-1; ADP-ribosyltransferase diphtheria toxin-like 5; ARTD5; Poly [ADP-ribose] polymerase 5A; Protein poly-ADP-ribosyltransferase tankyrase-1; TNKS-1; TRF1-interacting ankyrin-related ADP-ribose polymerase; Tankyrase I; Tankyrase-1; TANK1	Human	E. coli
	The TNKS1 protein is a polyADP-ribosyltransferase that is integral to multiple cellular processes, including the Wnt signaling pathway, telomere length regulation, and vesicle trafficking. In Wnt signaling, TNKS1 activates this pathway by poly-ADP-ribosylating AXIN1 and AXIN2, promoting their degradation. TNKS1 Protein, Human (His) is the recombinant human-derived TNKS1 protein, expressed by E. coli , with N-6*His labeled tag. The total length of TNKS1 Protein, Human (His) is 235 a.a., .

HY-P701632

	TNKS1 Protein, Human TNKS; Poly [ADP-ribose] polymerase tankyrase-1; ADP-ribosyltransferase diphtheria toxin-like 5; ARTD5; Poly [ADP-ribose] polymerase 5A; Protein poly-ADP-ribosyltransferase tankyrase-1; TNKS-1; TRF1-interacting ankyrin-related ADP-ribose polymerase; Tankyrase I; Tankyrase-1; TANK1	Human	E. coli
	The TNKS1 protein is a polyADP-ribosyltransferase that is integral to multiple cellular processes, including the Wnt signaling pathway, telomere length regulation, and vesicle trafficking. In Wnt signaling, TNKS1 activates this pathway by poly-ADP-ribosylating AXIN1 and AXIN2, promoting their degradation. TNKS1 Protein, Human is the recombinant human-derived TNKS1 protein, expressed by E. coli , with tag free. The total length of TNKS1 Protein, Human is 235 a.a., .

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: